Arizona lawmakers have approved two different bills focused on psychedelic therapy.
Senate passed a bill to create an advisory board tasked with studying the science of psilocybin, as well as state and federal policies surrounding the psychedelic, while the House separately approved a measure to fund clinical trials on ibogaine.
The Senate legislation from Sen. T. J. Shope (R) cleared the chamber in a 23-4 vote on Tuesday after it was significantly amended in committee, with members removing central provisions to establish licensed psilocybin service centers for adults seeking mental health treatment.
On the House side, the body advanced the ibogaine research legislation, sponsored by Rep. Justin Wilmeth (R), in a 36-22 vote on Monday, sending it to the Senate. It would provide funding for the state Department of Health Services (DHS) to “conduct a certified clinical research study on the use of ibogaine for the treatment of neurological diseases.”
An earlier version of Shope’s Senate psilocybin bill moved through both chambers last year with the regulated access components intact, but it was vetoed by the Democratic governor, who argued that “we do not yet have the evidence needed to support widespread clinical expansion.”
However, the year before, Gov. Katie
Read full article on Marijuana Moment
